Bracco Imaging S.p.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bracco Imaging S.p.A. - overview
Established
1927
Location
Milan, -, Italy
Primary Industry
Healthcare
About
Bracco Imaging S. p. A. is a leading firm specializing in the development and manufacturing of diagnostic imaging solutions, including contrast agents and advanced medical devices for improved patient diagnostics.
Founded in 1927 in Milan, Italy, Bracco Imaging S. p. A. focuses on creating innovative contrast agents and devices for diagnostic imaging.
The company has expanded its operations globally, catering to hospitals and healthcare providers. As a subsidiary of Bracco Group, it benefits from a strong foundation in medical imaging. The firm has seen strategic growth through its commitment to research and innovation, enhancing its product offerings across multiple geographies. Bracco specializes in the development and manufacturing of contrast agents and advanced medical devices primarily used in diagnostic imaging.
Their core product offerings include a diverse range of solutions for X-ray, CT, MRI, ultrasound, and nuclear medicine, aimed at enhancing the quality of medical imaging and improving diagnostic accuracy. These products assist healthcare professionals in identifying and diagnosing various medical conditions, directly contributing to better patient outcomes. Bracco serves a varied client base, including hospitals, imaging centers, and healthcare providers across North America, Europe, and Asia, demonstrating its commitment to innovation and research in addressing the evolving challenges within the healthcare industry. In 2023, Bracco reported a revenue of USD 552.
55 mn, with an EBITDA of USD 44. 28 mn. The company generates its revenue through the sale of diagnostic imaging products and services, structured around direct sales to healthcare facilities and partnerships with medical institutions. The pricing structure is tailored to meet the specific needs of clients, involving contracts for bulk purchases or ongoing supply agreements that ensure consistent access to essential products.
Bracco's flagship products, including proprietary contrast agents, are integral to these transactions, enhancing diagnostic capabilities in clinical settings. Bracco Imaging S. p. A.
is focused on launching innovative products designed to enhance diagnostic imaging solutions, with anticipated releases in the upcoming year. The company has plans to expand into new markets, specifically targeting regions in Asia and South America by 2025. Recent funding will be allocated to support these initiatives, emphasizing R&D in product development and market entry strategies. This approach aims to strengthen Bracco's position in the global healthcare market, ensuring that its offerings meet the evolving demands of medical professionals.
Primary Industry
Healthcare
Sub Industries
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories
Website
www.braccoimaging.com
Total Amount Raised
Subscriber access only
Bracco Imaging S.p.A. - timeline of key events
Bracco Imaging S.p.A. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 269,920,235 | 268,821,942 | 324,472,629 | 318,589,527 | 317,160,543 | 347,898,643 | 364,224,106 | 363,132,669 | 298,926,310 | 344,078,848 | 346,961,833 | 339,136,354 | - | - | - |
| % Revenue Growth (YoY) | - | (0.4%) | 20.7% | (1.8%) | (0.4%) | 9.7% | 4.7% | (0.3%) | (17.7%) | 15.1% | 0.8% | (2.3%) | - | - | - |
| EBITDA (USD) | 46,823,951 | 43,278,259 | 45,620,488 | 50,046,253 | 58,020,955 | 73,242,961 | 85,233,966 | 72,712,827 | 14,989,374 | 45,112,645 | 45,550,300 | 12,736,052 | - | - | - |
| Operating Income (USD) | 32,381,158 | 29,614,269 | 31,269,982 | 33,673,624 | 41,260,392 | 59,096,290 | 70,756,355 | 58,413,163 | 1,213,796 | 26,741,392 | 24,842,300 | (8,867,948) | - | - | - |
| Operating Margin | 12.0% | 11.0% | 9.6% | 10.6% | 13.0% | 17.0% | 19.4% | 16.1% | 0.4% | 7.8% | 7.2% | (2.6%) | - | - | - |
| % EBITDA Margin | 17.3% | 16.1% | 14.1% | 15.7% | 18.3% | 21.1% | 23.4% | 20.0% | 5.0% | 13.1% | 13.1% | 3.8% | - | - | - |
| NET Income (USD) | 47,960,330 | 49,429,614 | 374,832 | 41,562,957 | 38,991,745 | 76,475,352 | 86,702,259 | 67,857,296 | 43,772,776 | 62,316,784 | 186,947,707 | 125,156,907 | - | - | - |
| % Net Margin | 17.8% | 18.4% | 0.1% | 13.0% | 12.3% | 22.0% | 23.8% | 18.7% | 14.6% | 18.1% | 53.9% | 36.9% | - | - | - |
Bracco Imaging S.p.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Blue Earth Therapeutics Limited | - | ||||||||
| Trade Sale | Completed | Blue Earth Diagnostics Ltd. | - | ||||||||
| Trade Sale | Completed | ACIST Medical Systems, Inc. | - |
Displaying 1 - 3 of 3
Bracco Imaging S.p.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.